Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

personalized neoantigen vaccine NECVAX NEO1

A personalized, oral Ty21a-based neoantigen vaccine consisting of eukaryotic expression plasmid encoding patient-specific tumor neoantigens that are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon oral administration of personalized neoantigen vaccine NECVAX NEO1, the patient-specific neoantigens elicit a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens. Ty21a is a live-attenuated Salmonella typhi strain oral typhoid vaccine that is modified and used to deliver the neoantigens-encoding plasmids to the gut-associated lymphoid tissue.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:NECVAX NEO1
NECVAX-NEO1
NECVAXNEO1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search